Trailing-twelve-month (TTM) revenue is $11.09 Billion with a year-over-year growth of (7.27%). Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q2 FY2026Period ended 2025-09-30 | $2,890,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-24 |
| Q3 FY2026Period ended 2025-12-31 | $2,620,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-01-23 |
| Q4 FY2026Period ended 2026-03-31 | $2,783,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-22 |
| Q1 FY2027Period ended 2026-06-30 | $2,800,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-24 |
| TTM revenue | $11,093,000,000 |
Current P/S: $9,121,209,723 market capitalization ÷ $11,093,000,000 TTM revenue = 0.82x.
Market capitalization source: FMP quote. Quote observed 2026-09-23T19:50:10.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q1 FY2027 (2026-06-30): $2.80B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-23T19:50:20.331Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2026-03-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2024-03-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20212021-03-31 · USD | FY20222022-03-31 · USD | FY20232023-03-31 · USD | FY20242024-03-31 · USD | FY20252025-03-31 · USD | FY20262026-03-31 · USD |
|---|---|---|---|---|---|---|
| Cost Reimbursable Contract | $4.4B | $4.5B | $4.9B | $5.9B | $6.9B | $6.6B |
| Fixed-price Contract | $1.5B | $1.8B | $2.1B |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20192019-03-31 · USD | FY20202020-03-31 · USD | FY20212021-03-31 · USD | FY20222022-03-31 · USD | FY20232023-03-31 · USD | FY20242024-03-31 · USD |
|---|---|---|---|---|---|---|
| UNITED STATES | $6.4B | $7.2B | $7.7B | $8.1B | $9.0B | $10.5B |
$11.09B
$11.09 Billion
(7.27%)
vs. $11.96B a year ago (TTM)
+7.05%
5 Year compound annual growth rate
1 Year
(7.27%)
3 Year
+4.70%
5 Year
+7.05%
10 Year
+7.31%
15 Year
+4.54%
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2026 | $11.22B | ($763.00M) | (6.37%) |
| 2025 | $11.98B | +$1.32B | +12.36% |
| 2024 | $10.66B | +$1.40B | +15.15% |
| 2023 | $9.26B | +$895.21M | +10.70% |
| 2022 | $8.36B | +$504.76M | +6.42% |
| 2021 |
TTM Growth
(7.27%)
3-Year CAGR
+4.70%
5-Year CAGR
+7.05%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-23T19:50:20.331Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $2.4B |
| $2.1B |
| Time-and-materials Contract | $2.0B | $2.0B | $2.3B | $2.5B | $2.7B | $2.5B |
|---|
| $7.86B |
| +$395.10M |
| +5.29% |
| 2020 | $7.46B | +$759.80M | +11.33% |
| 2019 | $6.70B | +$536.44M | +8.70% |
| 2018 | $6.17B | +$358.11M | +6.16% |
| 2017 | $5.81B | +$403.75M | +7.47% |
